Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

BACKGROUND: Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiang, Stiekema, Lotte C. A., Stroes, Erik S. G., Groen, Albert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216641/
https://www.ncbi.nlm.nih.gov/pubmed/32393252
http://dx.doi.org/10.1186/s12944-020-01280-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216641/
https://www.ncbi.nlm.nih.gov/pubmed/32393252
http://dx.doi.org/10.1186/s12944-020-01280-0

Ejemplares similares